Bioequivalence Study Of Verapamil

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate bioequivalence of single doses of two verapamil formulations

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Verapamil

Criteria

Inclusion Criteria:

• Healthy male and/or female subjects

• Mass Index (BMI) of approximately 18 to 30 kg/m2

Exclusion Criteria:

• Any condition possibly affecting drug absorption

• A positive urine drug screen